Immupharma (IMM)

 

Latest News

Broker Forecast - finnCap issues a broker note on ImmuPharma PLC

finnCap today initiates coverage of ImmuPharma PLC (LON:IMM) with a buy investment rating and price target of 237p...

Holding(s) in Company

RNS Number: 7454X Immupharma PLC 28 November 2017 28 November 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Holding(s) in Company ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, has received notification from Alto Invest ("Alto") that Alto now holds 5,242,536 ordinary shares of 10p each in the...

Grant of Options

RNS Number: 4907X Immupharma PLC 24 November 2017 24 NOVEMBER 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Grant of Options ImmuPharma PLC (LSE:IMM) , ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 7,875,000 ordinar...

Lupuzor trial on track, says ImmuPharma

ImmuPharma is on track to report top line results from its 52-week, randomised, double-blinded, phase III clinical trial of ...

All News

DateHeadlineSource
12-12-17Broker Forecast - finnCap issues a broker note on ImmuPharma PLCStockMarketWire
28-11-17Holding(s) in CompanyRNS
24-11-17Grant of OptionsRNS
02-11-17Lupuzor trial on track, says ImmuPharma StockMarketWire
02-11-17Update on LupuzorT Pivotal Phase III StudyRNS
16-10-17Holding(s) in CompanyRNS
04-10-17ImmuPharma completes sharing agreement with Lanstead StockMarketWire
04-10-17Completion of Lanstead Sharing AgreementRNS
27-09-17ImmuPharma revenues riseStockMarketWire
27-09-17Interim ResultsRNS
26-09-17Preparation of Lupuzor'sT Regulatory SubmissionsRNS
21-09-17Update on LupuzorT Pivotal Phase III StudyRNS
19-09-17ImmuPharma schedules interims StockMarketWire
19-09-17Notification of Interim ResultsRNS
18-08-17AIM Rule 17 NoticeRNS
12-07-17Grant of OptionsRNS
30-06-17Result of AGMRNS
30-06-17Broker Forecast - Northland Capital issues a broker note on ImmuPharma PLCStockMarketWire
30-06-17Update on LupuzorT Pivotal Phase III StudyRNS
07-06-17Annual Report & Notice of AGMRNS
01-06-17ImmuPharma losses widenStockMarketWire
01-06-17Final ResultsRNS
22-05-17Notification of Full Year ResultsRNS
17-05-17Lupuzor study on track, says ImmuPharma StockMarketWire
17-05-17Update on Lupuzor Phase III StudyRNS
31-03-17New Employee Share Option Plan & Grant of OptionsRNS
31-03-17New Employee Share Option Plan & Grant of OptionsRNS
24-03-17ImmuPharma to present at Master Investor ShowRNS
22-03-17Holding(s) in CompanyRNS
20-03-17Holding(s) in CompanyRNS
20-03-17Holding(s) in CompanyRNS
10-03-17?4.1 Million Fund Raise via Accelerated BookbuildRNS
10-03-17Accelerated Bookbuild for the Issue of EquityRNS
06-03-17Holding(s) in CompanyRNS
17-02-17Holding(s) in CompanyRNS
25-01-17Update on Lupuzor Phase III StudyRNS
24-01-17Change of AdviserRNS
29-12-16Holding(s) in CompanyRNS
22-12-16ImmuPharma completes Lupuzor patient recruitment StockMarketWire
22-12-16Update on Lupuzor Pivotal Phase III StudyRNS

RSS feeds

  • Editorial news feed for LSE:IMM Editorial
  • Regulatory news feed for LSE:IMM Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account